Oral Hypoxia–Inducible Factor Prolyl Hydroxylase Inhibitor Roxadustat (FG-4592) for the Treatment of Anemia in Patients with CKD

BACKGROUND AND OBJECTIVES: Roxadustat (FG-4592), an oral hypoxia–inducible factor prolyl hydroxylase inhibitor that stimulates erythropoiesis, regulates iron metabolism, and reduces hepcidin, was evaluated in this phase 2b study for safety, efficacy, optimal dose, and dose frequency in patients with...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:Clin J Am Soc Nephrol
Autores principales: Provenzano, Robert, Besarab, Anatole, Sun, Chao H., Diamond, Susan A., Durham, John H., Cangiano, Jose L., Aiello, Joseph R., Novak, James E., Lee, Tyson, Leong, Robert, Roberts, Brian K., Saikali, Khalil G., Hemmerich, Stefan, Szczech, Lynda A., Yu, Kin-Hung Peony, Neff, Thomas B.
Formato: Artigo
Lenguaje:Inglês
Publicado: American Society of Nephrology 2016
Materias:
Original Articles
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC4891748/
https://ncbi.nlm.nih.gov/pubmed/27094610
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2215/CJN.06890615
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares